Rachman Jonathan 4
4 · OSI PHARMACEUTICALS INC · Filed Jun 7, 2010
Insider Transaction Report
Form 4
Rachman Jonathan
Sr VP, Diabetes/Obesity R&D
Transactions
- Disposition from Tender
Common Stock
2010-06-03$57.50/sh−2,124$122,130→ 12,278 total - Disposition to Issuer
Common Stock
2010-06-03$57.50/sh−12,278$705,985→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2010-06-03$57.50/sh−22,000$1,265,000→ 0 totalExercise: $46.93Exp: 2015-05-01→ Common Stock (22,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-06-03$57.50/sh−2,717$156,228→ 0 totalExercise: $23.83Exp: 2012-11-30→ Common Stock (2,717 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-06-03$57.50/sh−8,000$460,000→ 0 totalExercise: $37.74Exp: 2013-12-12→ Common Stock (8,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-06-03$57.50/sh−11,250$646,875→ 0 totalExercise: $47.29Exp: 2014-12-11→ Common Stock (11,250 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-06-03$57.50/sh−25,000$1,437,500→ 0 totalExercise: $33.62Exp: 2015-12-15→ Common Stock (25,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-06-03$57.50/sh−20,000$1,150,000→ 0 totalExercise: $35.40Exp: 2019-12-14→ Common Stock (20,000 underlying)
Footnotes (2)
- [F1]Represents the number of unvested Restricted Stock Units that were canceled in exchange for a cash payment of $57.50 per unit in accordance with the Agreement and Plan of Merger, dated as of May 16, 2010, among OSI Pharmaceuticals, Inc., Astellas Pharma Inc., Astellas US Holding, Inc. and Ruby Acquisition, Inc.
- [F2]These stock options were canceled in exchange for a cash payment in accordance with the Agreement and Plan of Merger, dated as of May 16, 2010, among OSI Pharmaceuticals, Inc., Astellas Pharma Inc., Astellas US Holding, Inc. and Ruby Acquisition, Inc. The cash payment made with respect to each stock option equals the product of (x) the number of shares issuable upon the exercise of such option multiplied by (y) the excess, if any, of $57.50 over the exercise price per share for such option.